earnings
confidence high
sentiment positive
materiality 0.80
Biogen Q2 revenue $2.6B (+7% YoY), GAAP EPS $4.33, raises FY2025 guidance
BIOGEN INC.
2025-Q2 EPS
reported $5.97
vs consensus $3.94
▲ beat
(+51.6%)
- Q2 2025 revenue $2.6B (+7% YoY); GAAP EPS $4.33 (+8%); Non-GAAP EPS $5.47 (+4%).
- Raised FY2025 Non-GAAP EPS guidance to $15.50-$16.00 (from $14.50-$15.50); revenue now expected ~flat vs 2024.
- LEQEMBI U.S. in-market sales ~$63M (+20% sequential); global ~$160M incl. $35M one-time China shipment.
- SKYCLARYS global rev. ~$130M; U.S. ~$78M (+13% seq.); ZURZUVAE $46M (+68% seq.).
- Pipeline: salanersen advancing to registrational stage in SMA; felzartamab Phase 3 initiated in rare kidney diseases.